Cleveland BioLabs, Inc. (NASDAQ:CBLI) Cut to “Sell” at ValuEngine

ValuEngine lowered shares of Cleveland BioLabs, Inc. (NASDAQ:CBLI) from a hold rating to a sell rating in a report released on Thursday, June 29th.

Cleveland BioLabs (NASDAQ:CBLI) traded down 3.04% during trading on Thursday, reaching $2.55. The company had a trading volume of 20,618 shares. The stock’s market capitalization is $28.76 million. The firm has a 50-day moving average of $2.99 and a 200-day moving average of $2.54. Cleveland BioLabs has a 1-year low of $1.22 and a 1-year high of $5.55.

Cleveland BioLabs (NASDAQ:CBLI) last announced its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.15) earnings per share for the quarter. Cleveland BioLabs had a negative net margin of 111.40% and a negative return on equity of 28.45%. The business had revenue of $0.58 million for the quarter. On average, analysts anticipate that Cleveland BioLabs will post ($0.16) EPS for the current fiscal year.

WARNING: “Cleveland BioLabs, Inc. (NASDAQ:CBLI) Cut to “Sell” at ValuEngine” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.chaffeybreeze.com/2017/07/30/cleveland-biolabs-inc-nasdaqcbli-downgraded-by-valuengine-to-sell-updated-updated-updated.html.

Cleveland BioLabs Company Profile

Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply